Abstract
Cefdinir is an extended-spectrum oral cephalosporin that is active against pathogens commonly seen in acute community-acquired bacterial sinusitis (ACABS), including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Two randomized, investigator-blind, multicenter trials (one in the United States and one in Europe) compared two dosage regimens of cefdinir (600 mg once a day for 10 days and 300 mg twice a day for 10 days) to amoxicillin-clavulanate (A-C) (500 mg three times a day for 10 days) for adult and adolescent patients with ACABS. Twelve hundred twenty-nine patients entered the U.S. study, 698 with antral puncture; 569 patients entered the European study, all with antral puncture. Clinical response (cure or improvement) was determined 7 to 14 days and 3 to 5 weeks posttherapy. Microbiologic eradication rates were determined 10 to 30 days posttherapy in a subset of patients who underwent pre- and posttherapy sinus aspirate culture. Rates of adverse events and treatment discontinuations due to adverse events were examined. Cefdinir, given once or twice daily, was as effective clinically (approximately 90% cure rate) as amoxicillin-clavulanate given three times daily in the treatment of ACABS. Microbiologic eradication rates were also similar in the three groups. The major side effect was mild diarrhea, occurring in approximately 20% of each group. Cefdinir caused fewer adverse events requiring treatment discontinuation.
Full Text
The Full Text of this article is available as a PDF (129.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berg O., Carenfelt C. Analysis of symptoms and clinical signs in the maxillary sinus empyema. Acta Otolaryngol. 1988 Mar-Apr;105(3-4):343–349. doi: 10.3109/00016488809097017. [DOI] [PubMed] [Google Scholar]
- Briggs B. M., Jones R. N., Erwin M. E., Barrett M. S., Johnson D. M. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):425–434. doi: 10.1016/0732-8893(91)90069-r. [DOI] [PubMed] [Google Scholar]
- Doern G. V., Brueggemann A., Holley H. P., Jr, Rauch A. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 May;40(5):1208–1213. doi: 10.1128/aac.40.5.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fung-Tomc J. C., Huczko E., Stickle T., Minassian B., Kolek B., Denbleyker K., Bonner D., Kessler R. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother. 1995 Feb;39(2):533–538. doi: 10.1128/aac.39.2.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gwaltney J. M., Jr Acute community-acquired sinusitis. Clin Infect Dis. 1996 Dec;23(6):1209–1225. doi: 10.1093/clinids/23.6.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gwaltney J. M., Jr, Phillips C. D., Miller R. D., Riker D. K. Computed tomographic study of the common cold. N Engl J Med. 1994 Jan 6;330(1):25–30. doi: 10.1056/NEJM199401063300105. [DOI] [PubMed] [Google Scholar]
- Gwaltney J. M., Jr, Scheld W. M., Sande M. A., Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol. 1992 Sep;90(3 Pt 2):457–462. doi: 10.1016/0091-6749(92)90169-3. [DOI] [PubMed] [Google Scholar]